Literature DB >> 18978819

High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia.

T Caravita, A Siniscalchi, A Tendas, L Cupelli, T Dentamaro, G Natale, A Spagnoli, P de Fabritiis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18978819     DOI： 10.1038/bmt.2008.360

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

1.  BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.

Authors:  M A V Marzolini; K J Thomson; J Dorman; S D'Sa
Journal:  Bone Marrow Transplant       Date:  2014-06-02       Impact factor: 5.483

2.  Successful treatment of cryoglobulinemic glomerulonephritis derived from Waldenström's macroglobulinemia by rituximab-CHOP and tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation.

Authors:  Noriaki Kawano; Naoko Ikeda; Shuro Yoshida; Yasuhiro Sugio; Kiyoshi Yamashita; Shigehiro Uezono; Toru Hayashi; Seiichiro Hara; Shigeyoshi Makino; Kazuya Shimoda; Akira Ueda
Journal:  Int J Hematol       Date:  2010-08-05       Impact factor: 2.490

Review 3.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Authors:  Stephen M Ansell; Robert A Kyle; Craig B Reeder; Rafael Fonseca; Joseph R Mikhael; William G Morice; P Leif Bergsagel; Francis K Buadi; Joseph P Colgan; David Dingli; Angela Dispenzieri; Philip R Greipp; Thomas M Habermann; Suzanne R Hayman; David J Inwards; Patrick B Johnston; Shaji K Kumar; Martha Q Lacy; John A Lust; Svetomir N Markovic; Ivana N M Micallef; Grzegorz S Nowakowski; Luis F Porrata; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Carrie A Thompson; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; Morie A Gertz
Journal:  Mayo Clin Proc       Date:  2010-08-11       Impact factor: 7.616
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.